We provide you with 20 years of free, institutional-grade data for IOBT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IOBT. Explore the full financial landscape of IOBT stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about IOBT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
IO Biotech, Inc.(NASDAQ:IOBT) 
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death...
Website: http://www.iobiotech.com
Founded: 2014
CEO / Founder: Mai-Britt Zocca
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends